GlassScriptPhysician profile
Cheryl R Ree
NPI 1275604316
$741.76
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $105 · 2021: $78.43 · 2022: $17.19 · 2023: $72.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.03 | 2019-2020 | |
| Novo Nordisk INC | $160.91 | 2019-2021 | |
| Lilly USA, LLC | $94.80 | 2019-2020 | |
| Amgen INC. | $62.63 | 2020-2023 | Prolia, Evenity |
| Amarin Pharma, INC. | $35.10 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.38 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $32.52 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $25.77 | 2021 | |
| Abbott Laboratories | $21.61 | 2023 | Freestyle Libre 2 |
| Abbvie INC. | $20.36 | 2019 | |
| Sanofi Pasteur INC. | $19.31 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2019 | |
| Janssen Biotech, INC. | $15.11 | 2019 | |
| Astellas Pharma US INC | $14.54 | 2019 | |
| Merck Sharp & Dohme LLC | $13.15 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Ree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.